In a major leap forward in cancer research, a team of Chinese scientists has unveiled a hidden metabolic collaboration between breast cancer cells and immune cells that accelerates tumor progression and undermines the body’s immune response. The findings, published in Cancer Cell on April 3, shed light on how tumors manipulate a vital nutrient—arginine—to both grow and escape detection by the immune system.
The study was spearheaded by Prof. Hu Hai, a leading oncologist and molecular biologist who serves at both the Hangzhou Institute of Medicine (HIM) under the Chinese Academy of Sciences and Zhejiang Cancer Hospital. He collaborated with Prof. Luo Manli from Sun Yat-Sen University and Prof. Li Hongde from HIM.
Using advanced single-cell and metabolic profiling technologies, the researchers discovered that breast cancer cells act as “arginine factories,” flooding the tumor microenvironment with this amino acid. While arginine is essential for healthy immune cell function, the cancer cells exploit it to reprogram nearby tumor-associated macrophages (TAMs)—a type of immune cell—effectively turning them into allies.
“These macrophages, once reprogrammed, stop fighting cancer and instead help protect the tumor by suppressing CD8+ T cells, which are our immune system’s frontline soldiers against cancer,” Prof. Hu explained.
The study revealed that TAMs absorb the cancer-derived arginine and convert it into polyamines, small molecules that alter their genetic expression. This transformation locks the macrophages into a state that supports tumor growth and dampens immune responses.
In preclinical trials, the team showed that disrupting this arginine-driven pathway restored T cell activity and significantly slowed tumor development. Their work suggests that combining drugs targeting arginine or polyamine metabolism with existing immunotherapies could offer a powerful new treatment strategy.
“This metabolic crosstalk may not be limited to breast cancer,” said Prof. Luo. “Other tumor types may use similar strategies to escape immune surveillance, which opens new doors for broad-spectrum therapeutic approaches.”
The study not only deepens the understanding of tumor-immune system dynamics but also paves the way for precision treatments that simultaneously cut off the tumor’s metabolic lifeline and revitalize the immune system.
“This is a promising step toward dual-action cancer therapies that can both starve the tumor and boost the body’s natural defenses,” Prof. Li added.
As researchers continue to explore the implications across various cancer types, this discovery could mark a paradigm shift in the development of next-generation cancer immunotherapies.
